Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

00:35 EDT 24th July 2014 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 28,000+

Wednesday 23rd July 2014

Celator: A Unique Drug Ratio Technology Company For Cancer

By Tony Schwartz, PhD: Company Overview Celator Pharmaceuticals (NASDAQ:CPXX) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various cancers. Their delivery platform, CombiPlex, consists of a nano-scale system that combines previously approved chemotherapy agents administered in fixed synergistic ratios. Combining drugs in...

Puma Biotechnology revises Neratinib licensing deal with Pfizer

US-based biopharmaceutical firm Puma Biotechnology has revised its licensing agreement with Pfizer for Puma's investigational drug PB272 (neratinib).

FDA approves reformulated drug to treat severe reactions to inhaled anesthetics during surgery

(Reuters) - Eagle Pharmaceuticals Inc said the U.S. Food and Drug Administration approved its drug to treat an inherited life-threatening condition called malignant hyperthermia (MH). The drugmaker's shares jumped about...

Shire plans to spend about $225 million on collaboration over potential Hunter syndrome drug

The drugmaker Shire plans to spend about $225 million in a joint effort with a privately held, U.S. firm to develop a potential treatment for the rare and life-threatening genetic disorder Hunter syndrome.

FDA Designates Dompe’s rhNGF-Based Treatment for Neurotrophic Keratitis Orphan Drug Status

Read more about FDA Designates Dompe’s rhNGF-Based Treatment for Neurotrophic Keratitis Orphan Drug StatusComments

Puma Biotech rockets on new neratinib data; amends deal with Pfizer

US development-stage company Puma Biotechnology saw its share more than triple to $190 in after-hours trading yesterday, when the released positive research results with its investigational breast cancer drug neratinib.

Idelalisib (Zydelig) Approved for CLL and Lymphoma

This oral drug has been generating great excitement among researchers, who welcome it as an alternative to chemotherapy. FDA Approvals

Fibrocell Science Takes Active Role to Support Dystrophic Epidermolysis Bullosa Patient Advocacy Group

Company to Address Potential of Genetically-Modified Autologous Fibroblasts for RDEB at 2014 DebRA Patient Care Conference Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announce...

UCB reports positive Phase III results for brivaracetam in epilepsy

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset seizure frequency and improved responder rates, both with statistical significance.

Celgene's cancer drug Isodax could re-activate dormant HIV and allow it to be detected

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows it to be detected, Reuters has reported from Danish scientists.

Dyax Corp. Announces Publication of Scientific Data for DX-2930 in Peer-Reviewed Journals

Dyax Corp. (NASDAQ: DYAX) today announced the online publication of scientific data for DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein (pKal), in two peer-reviewed journals. Dyax, a biopharmaceutical company focused on hereditary angioedema (HAE) and other plasma-kallikrein-mediated disorders, is developing DX-29...

Singulex Highlights Development Progress with Ultrasensitive Sgx Clarity™ System at AACC 2014

-- Company plans to commercialize an ultrasensitive IVD immunoassay system by 2016 -- Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, today outlined development progress toward commercializing, as early as 2016, an ultrasensitive immunoassay system for...

Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Blister and Other High Visibility Packaging markets. Global market for Blister and Other High Visibility Packaging is projected to reach US$41.3 billion by 2020, driven by increasing role of packaging as a marketing tool, growing consumer preferences for convenient, easy to open packages, rising need for product differentiation in commo...

Puma Biotechnology Shares Soar On Breast Cancer Drug Results

July 23, 2014By Renee Morad, BioSpace.com Breaking News StaffShares of

Pfizer Inc. Backs Out of Funding Puma Biotechnology Cancer Drug Trials

July 23, 2014By Renee Morad, BioSpace.com Breaking News Staff

Interview With Dinesh Thakur, ISPE Annual Meeting Keynote Speaker And Executive Chairman At Medassure Global Compliance Corporation

Dinesh S. Thakur is an expert and accomplished entrepreneur in pharmaceuticals, biomedical product development, drug regulation, and information technology. During his career, he held senior positions at Bristol-Myers Squibb Company, Ranbaxy Laborato...

Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced today that its second quarter 2014 financial results will be released after the market closes on Wednesday, August 6, 2014. Following the release, Aerie will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the company’s financial results and provide a general business update...

Eagle Pharma's drug to treat genetic condition gets U.S. approval

July 23 (Reuters) - Eagle Pharmaceuticals Inc said the U.S. Food and Drug Administration approved its drug to treat an inherited life-threatening condition called malignant hyperthermia (MH).

New Analysis Finds $5.4 Billion In Annual Lost Savings From Strategies Geared Toward Delaying Generic Drug Entry

WASHINGTON, July 23, 2014 /PRNewswire-iReach/ -- Use of Risk Evaluation and Mitigation Strategies (REMS) and other restricted access programs to delay generic market entry results in $5.4 billion in lost savings annually, according to a new survey and analysis by economic consulting firm Matrix Global Advisors (MGA). Logo - http://photos.prnewswire.com/prnh/20140723/129680 Required by the Food a...

Biogen revenue trounces forecast as MS drug sales surge

July 23 (Reuters) - Biogen Idec Inc reported sharply higher-than-expected quarterly revenue on surging sales of its new Tecfidera oral treatment for multiple sclerosis, and the company raised its full-year profit forecast.

Sanuvox Produces ASEPTIX² Movie Showcasing the Feature Benefits of the Company’s Latest Flagship Hospital Surface Disinfection System

Available on YouTube http://youtu.be/D27aj1iiUME the newly produced 6 minute movie highlights the features & benefits of the Sanuvox ASEPTIX² UV Hospital Disinfection System. Montreal, QC (PRWEB) July 23, 2014 Sanuvox has produced a six minute movie illustrating the features and benefits of the company’s latest system designed for hospital surface disinfection. The Sanuvox ASEPTIX²...

New Research Finds Pretreatment of Mesothelioma Cells with These Two Compounds Boosts Chemotherapy Response, According to Surviving Mesothelioma

A curcumin analog and a drug normally used to prevent rejection of organ transplants may make mesothelioma cells more susceptible to chemotherapy. Raleigh, NC (PRWEB) July 23, 2014 Researchers in Turkey say a compound called EF24, which is chemically similar to the yellow pigment in the spice turmeric, and an immunosuppressor called RAD001 helped scientists destroy mesothelioma cells in the lab....

NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable

NanoViricides, Inc. (NYSE MKT: NNVC) (the “Company”) reports that its President, Dr. Anil Diwan, was invited to participate in the 29th Annual Chief Executive of the Year Gala Reception & Dinner held at the New York Stock Exchange on Thursday, July 17, 2014. In addition, he was also invited to participate in the CEO Roundtable Discussion, on the to...

FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia

-- Novel Antidote Enables Quicker Response to Inherited Life-Threatening Condition -- -- Orphan Drug Designation may Provide Eagle Seven Years Market Exclusivity -- -- First Self Marketed Drug for Eagle with Shipments to begin Shortly -- Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today a...

Abuse of U.S. generic-drug rules costs consumers billions, report says

U.S. rules, aimed at ensuring prescription medicines are not misused, have been manipulated by brand-name drug companies to keep cheaper competition off the market, costing consumers billions of dollars, a report said on Wednesday. Protections set up...


Search BioPortfolio:
Advertisement

News Quicklinks

Advertisement